Ingelvac Provenza™

Protect your performance potential by vaccinating growing pigs against influenza A virus in swine (IAV-S), as early as day one.

INTRODUCING INGELVAC PROVENZA™

  • Ingelvac Provenza™ protects against multiple IAV-S strains1
  • Decreases nasal shedding, which reduces transmission in a population1
  • A live attenuated influenza vaccine (LAIV) breaks through maternal antibodies to stimulate immunity2
  • Provides protection before pigs are most vulnerable (eg, commingling, weaning)3  
  • Intranasal administration provides protection at the site of natural IAV-S infection4,5

Talk to your Boehringer Ingelheim sales representative to learn more about Ingelvac Provenza™.

Product Resources

Contact Info

Boehringer Ingelheim Vetmedica, Inc.

Swine Division
3902 Gene Field Road
St. Joseph, Missouri 64506
Phone 866-638-2226
Fax 816-676-4754

The science of intelligent protection

  • Efficacy and safety

    Lung lesion score > 2% was considered affected.
    A pig was considered positive for clinical signs if the pig ever had a score ≥ 1 for sneezing, coughing, nasal/ocular discharge, respiratory signs, or behavioral signs.
    llPigs were euthanized at 5 days postchallenge.

    INGELVAC PROVENZA™ WAS PROVEN SAFE FOR USE IN NEWBORN PIGS.1

    • A total of 997 pigs in 3 separate locations were administered 1 mL of Ingelvac Provenza™ intranasally at 1 day of age or older and observed daily for 14 days
    • At 2 sites (Missouri and Iowa), more than 90% of vaccinated pigs remained healthy for the entire observation period postvaccination
    • At the third site (North Carolina), 17% of vaccinated pigs remained healthy for the entire postvaccination period. Most observations of unthrifty pigs were related to abnormally hot and humid weather conditions and the subsequent effects on dam feed intake and lactation performance 
    • Clinical signs and mortality noted during the study was consistent with each respective site
  • Reduction in viral shedding1

     IIPigs were euthanized at 5 days postchallenge.

  • Evaluation of protection in the face of maternal antibodies2

    llPigs were euthanized at 5 days postchallenge.

Ingelvac Provenza™ provides game-changing protection when it is most needed

1. BIAH studies #2013200, 2013232, and 2014001 published on http://productdata.aphis.usda.gov. 

2. Genzow M, Goodell C, Kaiser TJ, Johnson W, Eichmeyer M. Live-attenuated influenza virus vaccine reduces virus shedding of newborn piglets in the presence of maternal antibody. Influenza Other Respir Viruses. In review [submission IRV-2017-172].

3. Alvarez J, Sarradell J, Kerkaert B, et al. Association of the presence of influenza A virus and porcine reproductive and respiratory syndrome virus in sow farms with post-weaning mortality. Prev Vet Med. 2015;121:240–245.

4. Vincent AL, Ma W, Lager KM, et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine. 2007;25:7999–8009.

5. Janke BH. Influenza A virus infections in swine: Pathogenesis and diagnosis. Vet Pathol. 2014;51:410–426.